Cardinal Health Q4 Profit Climbs, Sees Growth In FY27; Approves $5 Bln Buyback
Cardinal Health reported Q4 net earnings of $398 million, up 67%, and adjusted EPS of $2.91 versus $2.08 a year earlier, on revenue rising 5.8% to $63.672 billion. The company approved a $5.0 billion buyback, raising authorization to $6.4 billion, and declared a $0.5158 quarterly dividend. For FY27, it projects adjusted EPS growth of 13% to 15%, or $12.40 to $12.60.
How this was made
The 30-second read
Why it matters
Traders can update models using the provided FY2027 EPS range ($12.40 to $12.60) and assess capital return support from the increased buyback authorization ($6.4B total). Earnings quality may be scrutinized due to one-time IEEPA tariff refund impact referenced in the quarter.
Market read
A fresh earnings and guidance package plus a larger buyback authorization is a direct catalyst for CAH positioning ahead of the next earnings cycle.
What to watch
FY2027 segment profit growth ranges and the impact of tuck-in acquisitions (Strive Medical and Diabetes Health of AdaptHealth) may introduce integration and execution risk not fully captured by headline EPS growth.
Background
Cardinal Health reported Q4 results and simultaneously provided FY2027 adjusted EPS growth guidance, alongside an expanded share repurchase authorization and a quarterly dividend declaration.
Ticker impact
Cardinal Health reported Q4 profit and issued FY2027 adjusted EPS growth guidance plus a $5.0B buyback authorization increase to $6.4B total.
Bias toward upside follow-through as traders price in higher FY2027 EPS and capital return, though tariff-related items may add some earnings-quality noise.
The article provides concrete EPS and segment outlook ranges for FY2027, a quantified buyback authorization, and Q4 EPS/revenue figures, which are direct inputs to earnings and capital-return expectations.
Market effects
Signals continued profitability and capital return momentum in healthcare distribution/services, potentially supporting peer sentiment.
Primarily US-focused read-through via NYSE-listed healthcare services demand and capital return expectations.
Limited direct global spillover, but tariff-recovery references may keep attention on policy-driven earnings volatility in the sector.
Counterpoint
Tariff refund recognition (IEEPA) boosted results, so investors may discount part of the earnings strength when assessing sustainable earnings power.
Key entities
- companyCardinal Health, Inc.
Healthcare services company issuing FY2027 adjusted EPS guidance and increasing its share repurchase authorization to $6.4B total.
- personJason Hollar
CEO quoted on operational strength and segment profit growth.
- companyStrive Medical
Recently completed tuck-in acquisition referenced as part of the FY2027 outlook assumptions.
- companyDiabetes Health of AdaptHealth
Announced tuck-in acquisition referenced as part of the FY2027 outlook assumptions.
